New oral anticoagulants
| Autor: | Taki Galanis, Michael Palladino, Geno J. Merli, Lynda Thomson |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Arthroplasty Replacement Hip medicine.medical_treatment Administration Oral Knee replacement Dabigatran Postoperative Complications Atrial Fibrillation medicine Humans Arthroplasty Replacement Knee Intensive care medicine Stroke Rivaroxaban business.industry Anticoagulants Atrial fibrillation Venous Thromboembolism Hematology medicine.disease Clinical trial Venous thrombosis Anesthesia Apixaban Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Thrombosis and Thrombolysis. 31:310-320 |
| ISSN: | 1573-742X 0929-5305 |
| DOI: | 10.1007/s11239-011-0559-8 |
| Popis: | The new oral anticoagulants may prove to be one of the most significant innovations in clinical practice in the past 60 years. Apixaban and rivaroxaban are specific inhibitors of Factor Xa while dabigatran inhibits Factor IIa. The predictable pharmacological profile of these new agents will allow physicians to use these drugs without the need for routine coagulation monitoring which is the mainstay of warfarin therapy. In addition, these new agents have not been shown to have any food interactions and limited drug-drug interactions due to their minimal metabolism through the CYP450 system. This unique pharmacokinetic profile may usher in for clinicians a new era of managing thromboembolic disorders. In this paper, the pharmacology of these new oral anticoagulants are reviewed along with the major clinical trials in venous thromboembolism prevention in total hip and knee replacement orthopedic surgery, the treatment of venous thromboembolic disorders and stroke prevention in atrial fibrillation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink